Related Experiment Video
Updated: Jan 17, 2026

Direct Intraventricular Delivery of Drugs to the Rodent Central Nervous System
Published on: May 12, 2013
Gene therapy for children with X-linked myotubular myopathy: a plain language summary of publication for the ASPIRO
Perry B Shieh1, Wendy Hughes2, Marie Wood3
1Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Abstract:
What is this summary about? This summary describes the results of a research study (clinical trial) called ASPIRO that was published in the Lancet Neurology in 2023. This study looked at an investigational gene therapy called resamirigene bilparvovec (also known as AT132) as a possible treatment for children with a disease called X-linked myotubular myopathy (abbreviated as XLMTM).
More Related Videos
10:28Direct Reprogramming of Human Fibroblasts into Myoblasts to Investigate Therapies for Neuromuscular Disorders
Published on: April 3, 2021
06:51Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents
Published on: August 10, 2018
Related Concept Videos
Gene Therapy
Satellite Stem Cells and Muscular Dystrophy
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
X-Inactivation
X-linked Traits
Pleiotropy